Prophylaxis Against Malaria to Enhance Child Development (PROTECT Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

272 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-10-31

Study Completion Date

2021-08-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Each year, \~85.3 million pregnant women are at risk of becoming infected with Plasmodium falciparum(1). Among women in sub-Saharan Africa, most of whom have some degree of clinical immunity to malaria, malaria infection in pregnancy leads to placental malaria (PM), often without clinical symptoms in the mother. The systemic and placental changes that occur with malaria in pregnancy can adversely affect the developing fetal brain, an fetal brain injury strongly affects long-term childhood neurodevelopmental (ND) and behavior but there are no published studies to date on the impact of malaria in pregnancy on childhood ND. This study, conducted in Uganda, will address the effects of malaria in pregnancy and childhood ND and define mechanisms by which malaria may lead to ND impairment including micronutrient deficiencies. ND outcomes will be measured by the following neuropsychological and behavioral tests: Mullen Scales of Early Learning, the Color Object Association Test, the Early Childhood Vigilance Test, the Behavior Rating Scales, the Behavior Related inventory of Executive Function and the Child Behavior Checklist. These tests will be given at 12, 24, 36, and 60 months of age. This study will be nested in an ongoing Ugandan IRB approved interventional trial (PROMOTE-II) (NCT02163447). Blood sampling is being conducted in the PROMOTE-II protocol for research purposes. Some of that blood will be used to test for micronutrient deficiencies as well as other immune responses to malaria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria

NCT01555255

Malaria Placental Malaria Malaria in Pregnancy

UNKNOWN

Assessment of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi

NCT01120145

Malaria in Pregnancy

COMPLETED

Preventing Malaria During Pregnancy in Epidemic-prone Areas.

NCT00142207

Malaria, Falciparum

COMPLETED PHASE3

Prevention of Malaria in HIV-uninfected Pregnant Women and Infants

NCT02793622

Malaria

COMPLETED PHASE3

Malaria in Pregnancy: Nutrition and Immunologic Effects

NCT01115478

Malaria Low Birth Weight Anemia +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The PROMOTE-II randomized clinical trial in Tororo, Uganda, led by investigators from Makerere University in Uganda and the University of California-San Francisco (UCSF), provides an ideal setting to assess the effects of malaria prevention in pregnant women and their children on childhood ND. In PROMOTE-II Project 1,300 pregnant HIV-uninfected women will be randomized at 12-20 weeks of gestation to malaria prophylaxis with 3 doses of sulfadoxine-pyrimethamine (current standard of care), 3 doses of dihydroartemisinin-piperaquine (DP), or monthly DP. Their children will be randomized to receive DP prophylaxis monthly or every 3 months from 2 to 24 months age. The children will be followed for malaria episodes from birth to age 36 months. The proposed prospective study of child ND, the Prophylaxis against malaria To Enhance Child developmenT (PROTECT) study, will be nested within the PROMOTE-II Project 1 cohort. It is hypothesized that mothers on SP and mothers and children on less frequent prophylaxis will have more malaria episodes. The investigators predict that child ND will improve with more effective prophylaxis.

The central hypotheses of this study are that malaria prevention in pregnant women and their children improves child ND through 1) prevention of placental sequestration and inflammation and of consequent micronutrient deficiency in the fetus, and 2) reduction of systemic inflammation and endothelial activation that can lead to micronutrient deficiency and anemia during pregnancy and in early childhood and thus to alteration of brain structures particularly sensitive to such deficiencies (e.g., the hippocampus, myelin and the frontal lobe). The collaborative team, which has expertise in malaria in pregnant women and children, malaria pathogenesis, micronutrient deficiency, fetal and child neurodevelopment, and modeling of complex disease pathways, is well qualified to undertake the proposed research.

The specific aims of the study are:

Aim 1. Determine the effect of malaria prevention in pregnant women and their children on child ND. Hypotheses: 1) Long-term child ND improves with more effective chemoprevention in pregnant women and in their children. 2) The effect of malaria prevention on child ND persists through 36 months of age. Child ND will be assessed with a testing battery validated in previous studies by this group in Ugandan children. The investigators will test these hypotheses by comparing child ND at 12, 24, 36 and 60 months of age between treatment groups.

Aim 2. Identify the major mechanisms by which malaria prevention in pregnant women and children affects child ND. Hypotheses: 1) Malaria prevention in pregnant women affects child ND through prevention of placental sequestration and inflammation, with consequent prevention of prematurity, intrauterine growth retardation and fetal micronutrient deficiency. 2) Malaria prevention in pregnant women and in their children after birth improves child ND through reduction of systemic inflammation, endothelial activation, micronutrient deficiency and anemia, but the relative contributions of the factors differ in pregnant women compared to children. The investigators will test these hypotheses by conducting path analysis to determine if networks that include these paths explain a significant proportion of the difference in child ND between treatment groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neurobehavioral Manifestations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Enrolled in Makerere University-UCSF PROMOTE II study
2. HIV-uninfected
3. 12 months of age at the time of enrollment
4. Within 30 km of the clinic

Exclusion Criteria

1. Serious adverse event to the study drugs requiring cessation of study drug
2. Active illness at enrollment (child can be enrolled once active illness has been treated and they are back to baseline health)
3. Previous history of head trauma or coma in the child
4. Cerebral palsy or other severe neurologic disease
5. Known chronic illness requiring medical care
6. Major medical abnormalities on screening history of past health
7. Known developmental delay

Minimum Eligible Age

10 Months

Maximum Eligible Age

38 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No